SCHEMBL6353598

SCHEMBL6353598

O=C(O)Cc1ccc(Cn2cc(C(=O)c3ccc4ccccc4c3)c3cc(OCc4ccccc4)ccc32)cc1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 4/20 0.54
PPARG P37231 3/20 0.54
PPARA Q07869 3/20 0.54
LMNA P02545 3/20 0.51
ALDH1A1 P00352 2/20 0.51
LTB4R Q15722 3/20 0.51
LTB4R2 Q9NPC1 3/20 0.51
PLA2G2A P14555 3/20 0.50
POLB P06746 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CNR1 P21554 1/20 0.45
CNR2 P34972 1/20 0.45
NPC1 O15118 1/20 0.43
MAPT P10636 1/20 0.43
THRA P10827 1/20 0.43
THRB P10828 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6340736 0.87 CNR2 (0.57) PPARDPPARGPPARALMNAALDH1A1
SCHEMBL6346110 0.85 PPARD (0.52) PPARDPPARGPPARALMNAALDH1A1
SCHEMBL3386836 0.80 LTB4R (0.66) PPARDPPARGPPARALMNAALDH1A1
SCHEMBL7679573 0.78 SERPINE1 (0.59) PPARDPPARGPPARALMNAALDH1A1
SCHEMBL3203412 0.78 SERPINE1 (0.64) PPARDPPARGPPARALMNAALDH1A1
SCHEMBL18284168 0.76 LTB4R (0.52) PPARDPPARGPPARAALDH1A1LTB4R
SCHEMBL8166905 0.75 PPARD (0.74) PPARDPPARGPPARALMNAALDH1A1
SCHEMBL9207903 0.75 ALOX5AP (0.58) LMNAALDH1A1
SCHEMBL8175031 0.74 PPARD (0.72) PPARDPPARGPPARALMNAALDH1A1
SCHEMBL5894096 0.74 PLA2G2A (0.56) PPARDPPARGPPARALMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030153751-A1 Inhibitors of phospholipase enzymes AMERICAN HOME PRODUCTS CORPORATION 2003-08-14 US claimed
CN-1299347-A Inhibitor of phospholipase enzymes GENETICS INST (US) 2001-06-13 CN claimed
EP-1056719-A2 INHIBITORS OF PHOSPHOLIPASE ENZYMES GENETICS INSTITUTE, INC. (US) 2000-12-06 EP claimed
WO-1999043651-A2 INHIBITORS OF PHOSPHOLIPASE ENZYMES GENETICS INSTITUTE, INC. (US) 1999-09-02 WO claimed
US-6916841-B2 Inhibitors of phospholipase enzymes GENETICS INSTITUTE, LLC (US) 2005-07-12 US disclosed
US-20030153751-A1 Inhibitors of phospholipase enzymes AMERICAN HOME PRODUCTS CORPORATION 2003-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153751-A1 Inhibitors of phospholipase enzymes PLA2G4C, PLA2G4B, PLA2G4A PPARD 1392/4885PPARG 1457/4885PPARA 984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.